One of these studies [198] also described the effects of CD33-knockout in the APP/PS1 mouse model, in demonstrating that APP/PS1-CD33−/− mice displayed a significant decrease in amyloid plaque burden, without altering APP processing, compared to APP/PS1-CD33+/+ controls. Here, CD33 is linked to amyloidosis.